Context Therapeutics Investor Presentation Deck
Context Therapeutics Overview
Focus on
Women's Oncology
ONA-XR
oral PR antagonist
CLDN6 x CD3
bispecific antibody
Cash Guidance
→ Unmet clinical need in breast, ovarian, and endometrial cancers
ONA-XR is novel, potentially first-in-class progesterone receptor (PR) antagonist
→ Q4 2022 expected initiation of Phase 1b/2 ELONA trial to evaluate elacestrant (oral SERD) plus ONA-XR
Q4 2022 expected preliminary data from three ongoing Investigator-Sponsored Trials (IST)
Claudin 6 (CLDN6) is uniquely expressed in certain adult and pediatric cancers
Developing a highly selective CLDN6 x CD3 bispecific antibody
→ On track for Candidate selection in Q4 2022 and IND submission in Q1 2024
3 Context Therapeutics Inc. - Sept. 2022
Executive Summary
→ Expected cash runway into Q1 2024View entire presentation